Skip to content

Study · Randomized controlled trial · n = 945 · 2009

4 results

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Dec 2008Cited by 181 (Europe PMC)

PMID19047297 (opens in a new tab)PMCIDPMC2645096 (opens in a new tab)DOI10.1200/jco.2007.12.3752 (opens in a new tab)PepBankPUB-19047297
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, adjuvant goserelin did not increase cardiovascular mortality after median follow-up of 8.1 years.

    In plain wordsIn men with locally advanced prostate cancer, cardiovascular mortality did not increase with goserelin plus radiation versus radiation alone.

    Peptide
    Goserelin
    Outcome
    No significant changeCardiovascular mortality at median follow-up
    Study

    n = 945

    Comparator
    Radiation therapy alone
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Cardiovascular-related deaths
    117 deaths
    Both arms combined

    Source sentences

    Summary
    After a median follow-up of 8.1 years, there were 117 cardiovascular-related deaths but no treatment-related increase in cardiovascular mortality.
    1 context sentence
    Summary · context
    Between 1987 and 1992, 945 men with locally advanced prostate cancer were randomly assigned to RT and adjuvant goserelin or RT alone.
  2. 02HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, cardiovascular mortality was 8.4% with adjuvant goserelin versus 11.4% without it at 9 years (P = .17).

    In plain wordsIn men with locally advanced prostate cancer, cardiovascular mortality at 9 years did not differ significantly with versus without adjuvant goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeCardiovascular mortality at 9 years
    Study

    n = 945

    Comparator
    Radiation therapy alone
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Cardiovascular mortality at 9 years
    8.4%
    Adjuvant goserelin
    Cardiovascular mortality at 9 years
    11.4%
    Without adjuvant goserelin

    Source sentences

    Summary
    At 9 years, cardiovascular mortality for men receiving adjuvant goserelin was 8.4% v 11.4% for men treated without adjuvant goserelin (Gray's P = .17).
    1 context sentence
    Summary · context
    Between 1987 and 1992, 945 men with locally advanced prostate cancer were randomly assigned to RT and adjuvant goserelin or RT alone.
  3. 03HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, treatment with adjuvant goserelin was not significantly associated with increased cardiovascular mortality risk (adjusted HR = 0.73; 95% CI, 0.47 to 1.15; P = .16).

    In plain wordsIn men with locally advanced prostate cancer, adjusted cardiovascular mortality risk did not differ significantly with versus without adjuvant goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeAdjusted cardiovascular mortality risk
    Study

    n = 945

    Comparator
    Radiation therapy alone
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio, cardiovascular mortality
    0.73
    Goserelin vs radiation alone; 95% CI 0.47 to 1.15

    Source sentences

    Summary
    In multiple regression analyses, treatment arm was not significantly associated with increased risk of cardiovascular mortality (adjusted hazard ratio [HR] = 0.73; 95% CI, 0.47 to 1.15; P = .16;
    1 context sentence
    Summary · context
    Between 1987 and 1992, 945 men with locally advanced prostate cancer were randomly assigned to RT and adjuvant goserelin or RT alone.
  4. 04HumanRandomized controlled trialSafety outcome

    In men with locally advanced prostate cancer, cardiovascular mortality did not differ when censoring at salvage goserelin (HR = 0.99; 95% CI, 0.58 to 1.69; P = .97).

    In plain wordsIn men with locally advanced prostate cancer, cardiovascular mortality did not differ between groups when follow-up stopped at salvage goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeCardiovascular mortality censored at salvage goserelin
    Study

    n = 945

    Comparator
    Radiation therapy alone
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio, cardiovascular mortality (censored at salvage goserelin)
    0.99
    Goserelin vs radiation alone; 95% CI 0.58 to 1.69

    Source sentences

    Summary
    when censoring at time of salvage goserelin therapy, HR = 0.99; 95% CI, 0.58 to 1.69; P = .97).
    1 context sentence
    Summary · context
    Between 1987 and 1992, 945 men with locally advanced prostate cancer were randomly assigned to RT and adjuvant goserelin or RT alone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.